Radiomics of Tumor Heterogeneity in ¹⁸F-FDG-PET-CT for Predicting Response to Immune Checkpoint Inhibition in Therapy-Naïve Patients with Advanced Non-Small-Cell Lung Cancer.

Regarding the subgroup of patients with a TPS score > 50%, the parameter PET-Skewness also showed a trend in favor of patients with a value below the above-mentioned threshold (HR for disease progression or death, 0.57; 95% CI, 0.22 to 1.48; p = 0.247; Figure 5 A).

also in 53,322 other papers